Clinical Trial Update: Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of rilotumumab in persistent/recurrent ovarian, fallopian tube, or primary peritoneal cancer has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Rilotumumab (rilotumumab)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-07